carnitine has been researched along with Cognition Disorders in 14 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the putative neurotherapeutic effects of the mitochondrial cofactors, L-carnitine, acetyl-L-carnitine, and alpha-lipoic acid; and to provide a rationale for investigating their efficacy in the treatment of neurocognitive deficits associated with mood disorders." | 8.84 | Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? ( Chow, CS; Kennedy, SH; Konarski, JZ; McIntyre, RS; Soczynska, JK; Woldeyohannes, HO, 2008) |
| "Twenty-nine patients with probable Alzheimer's disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry." | 5.43 | Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. ( Angiolillo, A; Corbi, G; Corso, G; Cristofano, A; Di Costanzo, A; Intrieri, M; La Marca, G; Russo, C; Sapere, N; Scapagnini, G; Vitale, M, 2016) |
| "To evaluate the putative neurotherapeutic effects of the mitochondrial cofactors, L-carnitine, acetyl-L-carnitine, and alpha-lipoic acid; and to provide a rationale for investigating their efficacy in the treatment of neurocognitive deficits associated with mood disorders." | 4.84 | Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? ( Chow, CS; Kennedy, SH; Konarski, JZ; McIntyre, RS; Soczynska, JK; Woldeyohannes, HO, 2008) |
| "Minimal hepatic encephalopathy (mHE) is common among patients with cirrhotic liver disease and causes significant morbidity and mortality." | 2.52 | Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy. ( Direkze, S; Jalan, R, 2015) |
| "Twenty-nine patients with probable Alzheimer's disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry." | 1.43 | Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia. ( Angiolillo, A; Corbi, G; Corso, G; Cristofano, A; Di Costanzo, A; Intrieri, M; La Marca, G; Russo, C; Sapere, N; Scapagnini, G; Vitale, M, 2016) |
| "Increasing evidence suggest that Alzheimer's disease (AD) is a heterogeneous disorder that includes several subtypes with different etiology and progression." | 1.40 | Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease. ( Cedazo-Mínguez, Á; Cifuentes, A; Ibáñez, C; Lodeiro, M; Simó, C, 2014) |
| " Our findings also suggest that ethnic traits may affect carnitine bioavailability as well as cognitive outcomes in this clinical context." | 1.36 | Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review. ( Abramson, RK; Cuturic, M; Hardin, JW; Moran, RR, 2010) |
| " Chronic administration of carnitine over time pre- and post-lesions seemed to partially ameliorate the cognitive deficits caused by the synaptic lesion." | 1.31 | Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine. ( Ando, S; Fukui, F; Iwamoto, M; Izumiyama, N; Kobayashi, S; Kon, K; Nakamura, H; Tadenuma, T; Takeda, Y; Waki, H; Watanabe, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lodeiro, M | 1 |
| Ibáñez, C | 1 |
| Cifuentes, A | 1 |
| Simó, C | 1 |
| Cedazo-Mínguez, Á | 1 |
| Yan, J | 1 |
| Huang, Y | 1 |
| Lu, Y | 1 |
| Chen, J | 1 |
| Jiang, H | 1 |
| Direkze, S | 1 |
| Jalan, R | 1 |
| Cristofano, A | 1 |
| Sapere, N | 1 |
| La Marca, G | 1 |
| Angiolillo, A | 1 |
| Vitale, M | 1 |
| Corbi, G | 1 |
| Scapagnini, G | 1 |
| Intrieri, M | 1 |
| Russo, C | 1 |
| Corso, G | 1 |
| Di Costanzo, A | 1 |
| Cuturic, M | 1 |
| Abramson, RK | 1 |
| Moran, RR | 1 |
| Hardin, JW | 1 |
| Owen, L | 1 |
| Sunram-Lea, SI | 1 |
| Malaguarnera, M | 1 |
| Listernick, R | 1 |
| Ando, S | 1 |
| Kobayashi, S | 1 |
| Waki, H | 1 |
| Kon, K | 1 |
| Fukui, F | 1 |
| Tadenuma, T | 1 |
| Iwamoto, M | 1 |
| Takeda, Y | 1 |
| Izumiyama, N | 1 |
| Watanabe, K | 1 |
| Nakamura, H | 1 |
| Külkens, S | 1 |
| Harting, I | 1 |
| Sauer, S | 1 |
| Zschocke, J | 1 |
| Hoffmann, GF | 1 |
| Gruber, S | 1 |
| Bodamer, OA | 1 |
| Kölker, S | 1 |
| Soczynska, JK | 1 |
| Kennedy, SH | 1 |
| Chow, CS | 1 |
| Woldeyohannes, HO | 1 |
| Konarski, JZ | 1 |
| McIntyre, RS | 1 |
| Vanhooren, GT | 1 |
| Tempesta, E | 1 |
| Troncon, R | 1 |
| Janiri, L | 1 |
| Colusso, L | 1 |
| Riscica, P | 1 |
| Saraceni, G | 1 |
| Gesmundo, E | 1 |
| Calvani, M | 1 |
| Benedetti, N | 1 |
| Pola, P | 1 |
| Bonavita, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of PeakATP (Adenosine 5' - Triphosphate Disodium) Supplementation vs. Placebo on Measures of Mood, Reaction Time and Cognitive Performance[NCT05100589] | 35 participants (Actual) | Interventional | 2021-10-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for carnitine and Cognition Disorders
| Article | Year |
|---|---|
Diagnosis and Treatment of Low-Grade Hepatic Encephalopathy.
Topics: Accidental Falls; Ammonia; Carnitine; Cognition Disorders; Electroencephalography; Gastrointestinal | 2015 |
Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose, oxygen, pyruvate, creatine, and L-carnitine.
Topics: Adenosine Triphosphate; Aging; Brain; Carnitine; Cognition; Cognition Disorders; Creatine; Energy Me | 2011 |
Carnitine derivatives: clinical usefulness.
Topics: Acetylcarnitine; Cardiotonic Agents; Cardiovascular Diseases; Carnitine; Cognition Disorders; Depres | 2012 |
Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders?
Topics: Acetylcarnitine; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carnitine; Cl | 2008 |
2 trials available for carnitine and Cognition Disorders
| Article | Year |
|---|---|
Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism.
Topics: Acetylcarnitine; Adult; Alcoholism; Carnitine; Clinical Trials as Topic; Cognition Disorders; Double | 1990 |
Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain.
Topics: Acetylcarnitine; Aged; Aged, 80 and over; Anxiety Disorders; Carnitine; Cognition Disorders; Depress | 1986 |
8 other studies available for carnitine and Cognition Disorders
| Article | Year |
|---|---|
Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Arginine; Biomarkers; Carnitine; | 2014 |
Repeated administration of ketamine can induce hippocampal neurodegeneration and long-term cognitive impairment via the ROS/HIF-1α pathway in developing rats.
Topics: Analgesics; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Calcium Channel Blockers; Carni | 2014 |
Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Biomarkers; Body Mass Index; Calibration; Carnitine; | 2016 |
Clinical outcomes and low-dose levocarnitine supplementation in psychiatric inpatients with documented hypocarnitinemia: a retrospective chart review.
Topics: Adult; Aged; Antimanic Agents; Black or African American; Brain Diseases, Metabolic; Carnitine; Cogn | 2010 |
A 14-year-old boy with vomiting.
Topics: Abdominal Pain; Adolescent; Brain Ischemia; Carnitine; Cognition Disorders; Diagnosis, Differential; | 2012 |
Animal model of dementia induced by entorhinal synaptic damage and partial restoration of cognitive deficits by BDNF and carnitine.
Topics: Aging; Alzheimer Disease; Animals; Botulinum Toxins, Type A; Brain-Derived Neurotrophic Factor; Carn | 2002 |
Late-onset neurologic disease in glutaryl-CoA dehydrogenase deficiency.
Topics: Age of Onset; Aged; Atrophy; Brain Diseases, Metabolic, Inborn; Carnitine; Cerebral Cortex; Cognitio | 2005 |
[Valproic acid and stupor].
Topics: Carnitine; Cognition Disorders; Humans; Male; Middle Aged; Valproic Acid | 1991 |